Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01679990 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)
A Phase 2 study, sponsored by Pluristem.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT01679990: Completed Phase 2 study, sponsored by Pluristem.
NCT01679990 is a Phase 2 study that has completed, run by Pluristem. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01679990, a Phase 2 study, has completed, sponsored by Pluristem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The objective of the study is to establish the safety profile of Intramuscular PLX-PAD injections and to evaluate the clinical efficacy of it in IC subjects comprising of 4 treatment groups: 1. Double treatment of PLX-PAD low dose 2. Double treatment of PLX-PAD high dose 3. Double treatment of Placebo 4. Single treatment of PLX-PAD high dose and additional treatment of Placebo. Subjects will receive the assigned treatment twice to the affected leg, within 12-weeks interval between each treatment. The study will be comprised of 5 stages: Screening period of up to 4 weeks,first treatment of PLX-PAD or placebo followed by additional injection after 12 weeks and with follow-up of 12 months post second injection
Interventions
- BIOLOGICAL PLX-PAD Low dose
- BIOLOGICAL PLX-PAD high doses
- BIOLOGICAL Double Placebo
- BIOLOGICAL high dose +Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2012-11-05 |
| Est. Completion | 2019-02-09 |
| Phase | Phase 2 |
What the finished NCT01679990 record still lists
NCT01679990 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 4 interventions - of which PLX-PAD Low dose is the first listed.
NCT01679990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01679990 about?
NCT01679990 is a clinical study titled "Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)". The objective of the study is to establish the safety profile of Intramuscular PLX-PAD injections and to evaluate the clinical efficacy of it in IC subjects comprising of 4 treatment groups: 1. Double treatment of PLX-PAD low dose 2. Double treatment of PLX-PAD high dose 3. Double treatment of Pla...
What is the current status of trial NCT01679990?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2012-11-05. Estimated completion is 2019-02-09.
What interventions are being tested in trial NCT01679990?
The interventions under investigation include: PLX-PAD Low dose (BIOLOGICAL), PLX-PAD high doses (BIOLOGICAL), Double Placebo (BIOLOGICAL), high dose +Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT01679990?
This trial is sponsored by Pluristem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01679990's enrollment target sits among peer trials
180 365th of 2000 higher than 1,610 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI